CHINH T. NGUYEN MD
Prescription History 1497899439
Internal Medicine - Infectious Disease in Baltimore, MD

NPI Status: Active since February 15, 2007

Contact Information

725 W LOMBARD ST
INFECTIOUS DISEASES
BALTIMORE, MD
ZIP 21201
Phone: (410) 706-7560
Fax: (410) 706-1992

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for CHINH T. NGUYEN MD, an active Infectious Disease specialist practicing in Baltimore, MD. Our medical registry currently tracks 2 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 24 documented patient claims. Among these therapy options, the most frequently utilized medication is Descovy, which accounts for 12 claims alone.

Medication Index

No matching medications currently found on file.

Descovy

Generic Formulation: Emtricitabine/Tenofov AlafenamSpecialty: Internal Medicine
Provider Metrics Summary
Total Claims 12
30-Day Fills 12.0
Days Supply 360
MD State Average Benchmarks
Peer Average Claims32.0
Peer Average 30-Day Fills34.0
Peer Average Days Supply1,019
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 62.5% less volume than the regional standard for practitioners inside MD. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $28,199.72 across this reporting matrix range.

Provider Avg Cost Per Claim

$2,349.98

State Avg Cost Per Claim

$2,275.09

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This product is used with other HIV medications to help control HIV infection. It helps to decrease the amount of HIV in your body so your immune system can work better. This lowers your chance of getting HIV complications (such as new infections, cancer) and improves your quality of life. This product is a combination of two different drugs: emtricitabine and tenofovir alafenamide. Emtricitabine is called a nucleoside reverse transcriptase inhibitor, while tenofovir alafenamide is called a nucleotide reverse transcriptase inhibitor. They are often called NRTIs. This product should not be used by itself to help control HIV infection. Doing so can make your treatment less effective. Use combination treatment with at least one other HIV medication. This product is also approved in the US to help prevent HIV infection in people who have a high risk for infection. Some things that increase risk include having a partner infected with HIV, having unprotected sex, having multiple sex partners, infection with a sexually transmitted disease-STD, or use/abuse of drugs or alcohol. Emtricitabine/tenofovir alafenamide is not a cure for HIV infection. To decrease your risk of spreading HIV disease to others, continue to take all HIV medications exactly as prescribed by your doctor. Use an effective barrier method (latex or polyurethane condoms/dental dams) during sexual activity as directed by your doctor. Do not share personal items (such as needles/syringes, toothbrushes, and razors) that may have contacted blood or other body fluids. Consult your doctor or pharmacist for more details.

Tivicay

Generic Formulation: Dolutegravir SodiumSpecialty: Internal Medicine
Provider Metrics Summary
Total Claims 12
30-Day Fills 12.0
Days Supply 360
MD State Average Benchmarks
Peer Average Claims37.0
Peer Average 30-Day Fills39.2
Peer Average Days Supply1,148
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 67.6% less volume than the regional standard for practitioners inside MD. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $27,830.79 across this reporting matrix range.

Provider Avg Cost Per Claim

$2,319.23

State Avg Cost Per Claim

$2,387.92

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Dolutegravir is used with other HIV medications to help control HIV infection. It helps to decrease the amount of HIV in your body so your immune system can work better. This lowers your chance of getting HIV complications (such as new infections, cancer) and improves your quality of life. Dolutegravir belongs to a class of drugs known as integrase inhibitors. It blocks the virus from growing and infecting more cells. Dolutegravir is not a cure for HIV infection. To decrease your risk of spreading HIV disease to others, continue to take all HIV medications exactly as prescribed by your doctor. Use an effective barrier method (latex or polyurethane condoms/dental dams) during sexual activity as directed by your doctor. Do not share personal items (such as needles/syringes, toothbrushes, and razors) that may have contacted blood or other body fluids. Consult your doctor or pharmacist for more details.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like CHINH T. NGUYEN MD provides transparency into local medical care patterns within Baltimore, MD.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Infectious Disease** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.